Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | Anthracycline benefit in early HR+/HER2- breast cancer

Nan Chen • 13 Dec 2024
SABCS 2024
Breast Cancer Cyclophosphamide
TAILORx

Nan Chen, MD, University of Chicago, Chicago, IL, discusses findings from the TAILORx trial (NCT00310180), which assessed chemotherapy regimens in early-stage HR+/HER2-negative breast cancer. Patients with a high recurrence score may derive greater benefit from anthracycline-containing regimens compared to taxane and cyclophosphamide alone, with significant improvements in recurrence-free and distant recurrence-free survival at 5 years. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nan Chen

Evaluating anthracycline benefits in breast cancer through recurrence scores
0:44
Evaluating anthracycline benefits in breast cancer through recurrence scores
Nan Chen • 13 Dec 2024
Balancing benefits and risks of anthracycline therapy in breast cancer
0:54
Balancing benefits and risks of anthracycline therapy in breast cancer
Nan Chen • 13 Dec 2024

Related Videos

Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals